Orion Oyj Class A · OMXHEX:ORNAV
Orion Oyj Class A — H1 2006 Earnings Presentation
14 slides from Orion Oyj Class A's earnings presentation, Aug 7, 2006
Slide 1: Orion Group financial review pro forma 1-6/2006
Orion Group financial review pro forma 1-6/2006 7 August 2006 The figures in the review have been carvved out from the financial statements of the demerged Orion Orion Corporation AA, Communications 7.8.2006 1 Orion Group as of 1 July 2006 •Proprietary Products patented prescription Pharmaceuticals
Slide 2: 13 key global pharma markets in 5/2005–4/2006
13 key global pharma markets in 5/2005 –4/2006 Source: IMS Health Retail Drug Monitor 7/2006 Pharma sales Change on Break- 5/05 - 4/06 comparative down USD billion period North America 199.5 +4 % 54 % Europe top 5 90.4 +4 % 24 % Japan 58.0 +4 % 15 % Latin America top 3 17.7 +23 % 5% Australia / New
Slide 3: Finnish pharmaceutical market in 1-6/2006
Finnish pharmaceutical market in 1-6/2006 • Total pharmaceutical wholesales were EUR 855 (862) million, change -0,1 % (+8,8 %) • Wholesales of Orion’ s pharmaceutical products were EUR 75.7 million, 9 % down from the comparative period. Orion’ s market share was 8.9 % (9.9 %) – Orion is the 2nd larg
Slide 4: Orion key figures 1-6/2006 vs 1-6/2005
Orion key figures 1-6/2006 vs 1-6/2005 1-6/2006 1-6/2005 Change 2005 IFRS IFRS % IFRS Net sales, EUR million 329,8 295,6 +11,6% 585,6 Operating profit, EUR million 105,8 83,4 +26,9% 155,2 % of net sales 32,1% 28,2% 26,5% Profit before taxes, EUR million 105,9 82,7 +28,0% 154,3 Earnings per share, EU
Slide 5: Group EBIT by annual quarters
Group EBIT by annual quarters EBIT without milestone payments Contribution of milestones to EBIT EUR m 70 60 62,9 50 40 45,3 45,9 32,1 42,9 38,1 30 4,1 28,0 20 25,9 10 0 6,7 7-9/´04 10-12/'04 1-3/¨05 4-6/´05 7-9/´05 10-12/´05 1-3/'06 4-6/'06 Orion Corporation AA, Communications 7.8.2006 9 Balance Sh
Slide 6: Ownership base on 31 July 2006
Orion B in relation to OMX Portfolio and Europe Pharmaceutical indeces 3 July –3 Aug. 2006 110 3. Aug. 2006 Orion B 95.47 Europe Pharmaceutical 99.28 OMX Portfolio 99.16 100 90 80 Orion Corporation AA, Communications 7.8.2006 11 Ownership base on 31 July 2006 House- holds On 31 July 2006: Public 49,
Slide 7: Net sales and EBIT 1-6/2006 by business segments
Net sales and EBIT 1-6/2006 by business segments Net sales EBIT EUR m Change EUR m Change Pharmaceuticals 309,2 +12,1 % 105,3 +25,0 % Diagnostics 21,6 +3,9 % 4,5 +20,5 % Group items -1,1 -7,4 % -4,0 -13,2 % Group total 329,8 +11,6 105,8 +26,9 % Orion Corporation AA, Communications 7.8.2006 13 Net sa
Slide 8: Net sales by geographic segments in 1-6/2006
Net sales by geographic segments in 1-6/2006 Other markets 7% North America 7% Finland 27% Scandinavia Other Europe 14% 45% Net sales total EUR 329.8 million Orion Corporation AA, Communications 7.8.2006 15 Pharmaceuticals business in 1-6/2006 EUR m 1-6/2006 1-6/2005 Change 2005 Net sales 309,2 275,
Slide 9: 10 best-selling drugs of Orion
10 best-selling drugs of Orion Change on EUR 158.1 million, Net sales, EUR million 1-6/2006 comp. 51% of total pharmaceutical period net sales Stalevo (Parkinson’ s Disease) 55,2 +56,1% Burana Comtess / Comtan (Parkinson’ s) 39,7 +10,0% Calcimagon Enanton Stalevo Domitor, Domosedan and 13,7 -4,1% Fa
Slide 10: Quarterly net sales from the entacapone franchise
Quarterly net sales from the entacapone franchise 2002–Q2/2006, by products 60 EUR million 50 40 Stalevo 30 Comtess+ 20 Comtan Franchise 10 total 0 02 02 03 03 04 04 05 06 02 02 03 03 04 04 05 05 05 06 2/ 4/ 1/ 3/ 1/ 2/ 3/ 4/ 1/ 2/ 3/ 4/ 1/ 2/ 3/ 4/ 1/ 2/ Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Orion Co
Slide 11: Situation of the Simdax project
Situation of the Simdax (i.v. levosimendan) project • Orion and Abbott Laboratories have started discussions about a possible additional Phase 3 clinical trial and its financing. • Orion will inform about the solutions as soon as reached. Orion Corporation AA, Communications 7.8.2006 21 Pharmaceutic
Slide 12: Diagnostics business in 1-6/2006
Diagnostics business in 1-6/2006 EUR m 1-6/2006 1-6/2005 Change 2005 Net sales 21,6 20,8 +3,9% 40,8 Operating profit, EBIT 4,5 3,7 +20,5% 6,3 • Orion Diagnostica showed low net sales growth in the second quarter, which together with the costs and accruals allocated to the period led to dampened prof
Slide 13: Outlook for 2006
Outlook for 2006 2 (3) Diagnostics business • Net sales will increase • Operating profit will improve from the previous year Orion Corporation AA, Communications 7.8.2006 25 Outlook for 2006 3 (3) • Due to one-off earnings items, the operating profit resulting from the Group items is anticipated to
Slide 14: Orion's calendar for rest of 2006
Orion’ s calendar for rest of 2006 • Shareholders’Meeting of the demerged Orion, Helsinki Monday, 16 October 2006 • Interim Report 7-9/2006 Thursday, 2 November 2006 (proforma figures for 1-6/2006 and 1-12/2005) • Capital Markets Day in London Wednesday, 22 November 2006 Orion Corporation AA, Commun